Atara Biotherapeutics
NASDAQ: ATRAThousand Oaks, US · Founded 2012 · Incorporated in Delaware · 105 employees on LinkedIn · 4 known investors
Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease. The company focuses on next-generation cell-based therapies designed for patients worldwide.
Also known as Atara · Atara Bio
Investors · 4
Company profile
researched Aug 2026Atara Biotherapeutics is an allogeneic T-cell immunotherapy company that develops therapies based on the biology of T cells for patients with cancer and autoimmune conditions. Its investigational therapies are designed as off-the-shelf products that can be delivered to patients from inventory within days rather than manufactured individually for each patient.
The company's portfolio includes EBVALLO (tabelecleucel), for which it issued regulatory updates in May 2025, and ATA3219, which is being evaluated in a Phase 1 study assessing safety and preliminary efficacy in B-cell non-Hodgkin lymphoma. Atara states it is the first company to receive an approval for an allogeneic T-cell immunotherapy.
Latest developments
In May 2025 Atara provided regulatory updates on EBVALLO (tabelecleucel). In November 2024 it reported third quarter 2024 financial results and operational progress, and in September 2024 it announced a $36 million registered direct offering. A Phase 1 study of ATA3219 in B-cell non-Hodgkin lymphoma is underway [0].
▸Full profile — market position, technology, go-to-market
Market position
Atara states that it is the first company ever to receive an approval for an allogeneic T-cell immunotherapy [0].
Off-the-shelf allogeneic T-cell products available for rapid delivery within days, combined with a manufacturing process able to yield over a thousand doses from one healthy donor, differentiate Atara's approach from patient-specific autologous cell therapy [0].
Technology
Atara's platform is built on allogeneic (donor-derived) T cells rather than patient-specific cells, allowing therapies to be stored as inventory and delivered rapidly. The company describes a scalable manufacturing process capable of producing more than a thousand doses from a single healthy donor, and a platform it characterizes as versatile enough to address a range of viral and non-viral disease-causing targets [0].
Go-to-market
Patients with difficult-to-treat cancers and autoimmune conditions, reached through medical professionals and clinical study sites [0].
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 2
by search overlapCompanies competing with Atara Biotherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 3
launches, deals, and filingsThe company announced a $36 million registered direct offering.
$36M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 1
primary sources listed
- Atara Biotherapeuticsatarabio.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Atara Biotherapeutics do?
- Atara Biotherapeutics is an allogeneic T-cell immunotherapy company developing off-the-shelf therapies for cancer and autoimmune disease.
- Who are Atara Biotherapeutics's investors?
- Atara Biotherapeutics's investors include Dag Ventures, EcoR1 Capital, HEALTHCARE ROYALTY PARTNERS, Kleiner Perkins.
- Where is Atara Biotherapeutics headquartered?
- Atara Biotherapeutics is headquartered in Thousand Oaks, US.